Medical device maker AngioDynamics beats Q4 revenue estimates

AngioDynamics

15/07/2025 11:40

Overview

AngioDynamics fiscal Q4 net sales rose 12.7%, beating analyst expectations, per LSEG data

Adjusted EPS for fiscal Q4 beat analyst estimates, per LSEG data

Co generated $16.2 mln free cash flow in Q4 due to strong growth

Outlook

AngioDynamics sees FY2026 net sales $305 - $310 mln

Company expects Med Tech net sales growth of 12% - 15%

AngioDynamics forecasts flat Med Device net sales growth

Company anticipates FY2026 gross margin 53.5% - 55.5%

Result Drivers

MED TECH GROWTH - AngioDynamics reported a 22% increase in Med Tech net sales, driven by innovative platform technologies, per CEO Jim Clemmer

OPERATIONAL EFFICIENCY - Positive adjusted EBITDA and $16.2 million free cash flow attributed to operational efficiency efforts

TARIFF HEADWINDS - Tariffs impacted gross margin by 204 basis points, but strategies are in place to mitigate future impacts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$80.20 mln
$74.30 mln (3 Analysts)
Q4 Adjusted EPS
Beat
-$0.03
-$0.12 (3 Analysts)
Q4 Adjusted Net Income
Beat
-$1 mln
-$4.97 mln (3 Analysts)
Q4 Net Income
-$6.10 mln
Q4 Adjusted EBITDA
$3.40 mln
Q4 Gross Margin
52.7%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AngioDynamics Inc is $16.00, about 39.8% above its July 14 closing price of $9.63

Press Release: ID:nBw8z4ZD8a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)